abbott uk

Name

abbott uk

Legal name

Abbott Laboratories Limited

Website

https://abbott.co.uk

Company type

Public

Founded year

1888

Operating status

Operating

Ownership category

akta.pro rank

Product category

Medical Devices and Diagnostics

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)

akta.pro secondary industry

Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies) (HLAHAHAL)

Keywords

• Continuous glucose monitoring
• Medical device diagnostics
• Neuromodulation therapy systems
• Diabetes care products
• Molecular rapid testing

Headquarters

HQ city

Maidenhead

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D

Revenue model

1. Medical Devices - Glucose Monitoring: Sale of FreeStyle Libre sensors and systems through NHS prescription and direct consumer channels, with recurring sensor replacement revenue
2. Molecular Diagnostics: ID NOW rapid testing platform for infectious disease detection
3. Neuromodulation: NeuroSphere technology and associated neuromodulation devices for chronic pain and movement disorders
4. Nutritionals: Nutritional products and supplements for various health needs

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

Abbott UK manufactures, distributes and sells medical devices and diagnostics across five business areas: diabetes care (FreeStyle Libre continuous glucose monitoring sensors and digital ecosystem), neuromodulation (NeuroSphere Virtual Clinic, Infinity DBS, Proclaim XR SCS and Proclaim DRG implants), diagnostics (ID NOW molecular rapid testing, Afinion CRP, Alinity i and i-STAT laboratory instruments including TBI blood tests), cardiovascular products, and nutrition (The Prehabilitation Method guide and nutritional products). Revenue is generated principally through hardware and consumable sales to NHS Supply Chain Framework and Drug Tariff, alongside consumer-facing app downloads and direct-to-consumer sensor channels.

Product overview

Abbott UK operates as a global healthcare company with leading businesses spanning diagnostics, medical devices, nutritionals, and branded generic medicines. The product portfolio centers on the FreeStyle Libre continuous glucose monitoring family (FreeStyle Libre, FreeStyle Libre 2, FreeStyle Libre 3, and Libre Duo), which represents the world's most widely used CGM system. Supporting products include the FreeStyle LibreLink and LibreLinkUp apps, NeuroSphere Virtual Clinic for neuromodulation (compatible with Infinity DBS, Proclaim XR SCS, and Proclaim DRG systems), ID NOW molecular diagnostics platform, Afinion rapid diagnostic tests, and Alinity laboratory instruments. The portfolio also includes Lingo consumer biowearable and The Prehabilitation Method cancer care service. Integration partnerships include Ypsomed mylife YpsoPump, CamDiab CamAPS FX, and Novo Nordisk smart insulin pens through the Libre digital ecosystem.

Differentiator

Problem solved

Functional benefit

Brands

• FreeStyle Libre: Continuous glucose monitoring system for people with diabetes - includes FreeStyle Libre, FreeStyle Libre 2, and FreeStyle Libre 3 sensors
• NeuroSphere
• AmpuNATION
• LibreLink
• Lingo
• Prehabilitation Method
• ID NOW

Products and services

• FreeStyle Libre Portfolio Continuous glucose monitoring (CGM) system consisting of a sensor worn on the back of the upper arm for up to 14 days, paired with a handheld reader or smartphone. Includes FreeStyle Libre, FreeStyle Libre 2 and FreeStyle Libre 3 variants. Used by people with Type 1 and Type 2 diabetes in the UK and across more than 60 countries.
• Libre Duo and Libre Duo 10 Day World's first dual glucose-ketone sensing technology that continuously measures both glucose and ketone levels every minute. Libre Duo offers up to 15 days of wear for adults 18+; Libre Duo 10 Day offers up to 10 days of wear for ages 2+. Integrates with the Libre digital ecosystem and is compatible with leading automated insulin delivery systems. Alerts users to rising ketones that can lead to diabetic ketoacidosis.
• FreeStyle LibreLink App Smartphone app compatible with FreeStyle Libre sensors that displays real-time glucose readings, trends and integrates with Novo Nordisk smart insulin pens (NovoPen 6 and NovoPen Echo Plus) to show glucose and insulin dosing data together. Available on Apple App Store and Google Play.
• LibreLinkUp App Caregiver smartphone app that automatically receives glucose readings every minute and customised alarms for FreeStyle Libre 2 users. Designed for parents and caregivers of people with diabetes.
• NeuroSphere Virtual Clinic UK's first remote neuromodulation patient-care technology enabling patients with implanted neurostimulators to communicate with healthcare professionals and receive stimulation settings in real time via secure in-app video chat. Deployed across six UK specialist centres (Bristol, Glasgow, Kent and Canterbury, Leeds, Oxford and Southampton).
• Infinity DBS System Deep brain stimulation (DBS) system for patients with Parkinson's disease, disabling tremor or chronic intractable dystonia.
• Proclaim XR SCS System Spinal cord stimulation (SCS) system for chronic pain of the trunk and/or limbs, including the Proclaim XR rechargeable platform.
• Proclaim DRG Neurostimulation System Dorsal root ganglion (DRG) neurostimulation system for patients with chronic intractable pain of the lower limbs.
• ID NOW Molecular rapid testing platform delivering simple, fast and accurate results for COVID-19, flu, RSV and strep A at the point of care. Used by healthcare professionals and NHS settings in the UK.
• Afinion CRP Test Three-minute rapid blood test for C-reactive protein used in UK primary care to help identify patients who would benefit from antibiotics and reduce unnecessary prescribing.
• Alinity i Laboratory TBI Test Laboratory traumatic brain injury blood test running on the Alinity i instrument, producing results within 18 minutes to help evaluate mild TBI and concussion. CE-marked in December 2021.
• i-STAT TBI Plasma Test Rapid, portable handheld blood plasma test for concussion evaluation. CE-marked as the first rapid handheld blood plasma test for concussions.
• Lingo First-ever consumer biowearable from Abbott, positioned as a personal metabolic coach for health-conscious consumers without diabetes.
• The Prehabilitation Method Nutritional guide offering practical advice on how people can use the time between diagnosis and treatment to prepare for cancer treatment through better nutrition, physical activity and mental health support.

Quantifiable outcome

• 67% reduction in diabetes-related hospitalisations for Type 2 diabetes on basal insulin therapy
• +5 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability2 records

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Breakthrough T1DcoreStrategic or Co-development Partner · 27 May 2026Partnership with global Type 1 diabetes research organization supporting international expert consensus on continuous ketone monitoring guidelines for Libre Duo systems.
• Rankin (Photographer)minorGTM or Marketing Partner · 1 December 2024Creative partnership for AmpuNATION photography initiative capturing real people living with amputations to raise awareness of PAD and preventable amputations.
• Thursday (Dating App)minorGTM or Marketing Partner · 14 November 2024Marketing partnership for 'Discrimidating' campaign to raise awareness of diabetes stigma in dating, with Thursday sharing commitment to inclusivity.
• YpsomedcoreTechnology or Integration · 27 April 2023Strategic partnership to develop integrated automated insulin delivery (AID) system combining Abbott's FreeStyle Libre 3 sensor with Ypsomed's mylife YpsoPump and CamDiab's CamAPS FX algorithm for Type 1 diabetes management.
• CamDiabcoreTechnology or Integration · 27 April 2023Partnership to integrate CamDiab's CamAPS FX adaptive hybrid closed-loop algorithm with Abbott's FreeStyle Libre 3 sensor and Ypsomed pump for automated insulin delivery system.
• Novo NordiskcoreTechnology or Integration · 10 November 2022Integration partnership allowing FreeStyle LibreLink app to display glucose and insulin dosing data from Novo Nordisk's smart connected insulin pens (NovoPen 6 and NovoPen Echo Plus).

Scale indicators8 records

Expansion highlights6 records

Direct peers

• Ypsomed: Swiss insulin pump (mylife YpsoPump) manufacturer and Abbott partner; competes in the UK pump market while integrating FreeStyle Libre 3 in hybrid closed-loop systems.
• Dexcom: Leading global CGM manufacturer (Dexcom G6/G7) directly competing with FreeStyle Libre in the UK Type 1 and Type 2 markets through NHS reimbursement pathways and consumer channels.
• Medtronic: Diversified medical device company with UK presence across diabetes (Guardian/Simplera CGM and insulin pumps), neuromodulation (including DBS and SCS), and diagnostics; directly competes with Abbott across multiple UK franchises.
• LifeScan: Blood glucose monitoring company (OneTouch) competing with Abbott's consumer diabetes monitoring portfolio in retail pharmacy and NHS-adjacent channels.
• Tandem Diabetes Care: Insulin pump manufacturer whose t:slim X2 integrates with CGM systems; competes in the AID category alongside Abbott's Ypsomed/CamDiab partnership in UK diabetes care.
• Roche Diabetes Care: Major diabetes monitoring franchise (Accu-Chek blood glucose meters and emerging CGM); directly comparable as a competing diabetes-care device manufacturer in the UK.
• Insulet: Maker of the Omnipod tubeless insulin pump, increasingly integrated with CGM partners; competes with Abbott-linked pump ecosystems in UK automated insulin delivery.
• Ascensia Diabetes Care: Diabetes care company (Contour blood glucose meters) directly comparable as a competing glucose monitoring device manufacturer in the UK consumer and NHS markets.

Others

• Novo Nordisk: Partner whose NovoPen 6 and NovoPen Echo Plus smart insulin pens integrate with FreeStyle LibreLink; also a major competitor in the broader UK Type 2 diabetes market via GLP-1 therapies.

Broad incumbents

• Boston Scientific: Large neuromodulation incumbent with DBS and SCS systems that compete with Abbott's Infinity DBS and Proclaim XR/DRG franchises in the UK chronic pain and movement disorder market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/AbbottNews
• YouTubeyoutube.com/c/abbott
• Facebookfacebook.com/Abbott
• LinkedInlinkedin.com/company/abbott-
• Instagraminstagram.com/abbottglobal

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about abbott uk